Artificial intelligence research biotech Earendil Labs has penned an $885 million deal to use WuXi XDC’s linker-payload technology to create next-gen antibody-drug conjugates. | AI research biotech ...
Under the agreement, WuXi XDC will grant Earendil Labs an exclusive global license to its proprietary WuXiTecan-2 ...
WuXi XDC will grant Earendil Labs an exclusive global license to its proprietary technology for use against multiple specific targets.
US biotech Earendil Labs has entered a strategic collaboration with Hong Kong-listed WuXi XDC, securing an exclusive global license to the company’s WuXiTecan-2 payload-linker technology for multiple ...
The integration supports regulated custody options for XDC tokens and USDC on the XDC Network, contributing to the underlying infrastructure that corporates, exchanges, and financial institutions ...
WuXi XDC inks collaboration with Earendil Labs on WuXiTecan-2 payload-linker technology platform: Shanghai, China Monday, March 2, 2026, 17:00 Hrs [IST] WuXi XDC Cayman Inc. (WuXi ...
Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. ('WuXi XDC', stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results